Xcout Intel
XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney diseases, including specific pipeline candidates for gout and other conditions.
Subscribe to see XORTX Therapeutics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
XORTX Therapeutics Inc. at a glance
XORTX Therapeutics Inc. is a biotechnology company headquartered in Calgary, Canada. It is publicly listed (XRTX) with a market capitalisation of $648,879. Xcout tracks 26 named people at XORTX Therapeutics Inc., including Allen Davidoff (President & CEO).
XORTX Therapeutics Inc. leadership
- Allen DavidoffPresident & CEO
- Mika GrassoCo-CEO & Director
- Michael Scott BumbyChief Financial Officer
- Stacy EvansChief Business Officer
- Stephen Haworth MRCPChief Medical Officer
- Allen Warren DavidoffFounder, Co-CEO, President & Director
20 more named people on record for XORTX Therapeutics Inc., with roles, board committees and tenure — see the full roster →
Recent XORTX Therapeutics Inc. news
XORTX Therapeutics Inc. competitors
A few of XORTX Therapeutics Inc.'s closest competitors — see the full list of competitors and alternatives →
ENYO Pharma is a clinical-stage biopharmaceutical company that develops therapeutics for patients with impaired kidney function. Its lead compound, Vonafexor, is a small molecule currently in Phase 2 development to treat rare kidney diseases such as Alport syndrome and chronic kidney disease.
R1 Therapeutics is a renal-focused biotech company developing innovative, first-in-class, category-defining therapeutics for patients with kidney disease. Headquartered in San Francisco with additional offices in San Diego and Raleigh, the company started with lead asset AP306.
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Sironax is a biopharmaceutical company committed to developing new treatments by targeting underlying contributors of degeneration, including neurodegenerative, inflammatory, and metabolic disorders.
Synthorx, Inc., founded in 2014, is a biotechnology company headquartered in La Jolla, California, that engineered expanded genetic alphabet technologies to discover and develop novel protein therapeutics.
Centaurus Therapeutics is a clinical-stage biotechnology company that develops first-in-class small-molecule therapies targeting ceramides to treat cardio-kidney-metabolic (CKM) diseases. The company's lead oral asset, CNT2130, inhibits DES1 to reduce excess ceramide production and restore lipid balance for patients suffering from organ decline.
Get XORTX Therapeutics Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on XORTX Therapeutics Inc. in Xcout Intel
- 26 named people with titles, LinkedIn and board committees
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access